MERIDIAN, Idaho, Jan. 8 /PRNewswire-FirstCall/ -- RxElite, Inc. , a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today that as permitted under the registration rights agreement, it has voluntarily instructed all named selling stockholders to cease using the company’s Registration Statement on Form SB-2 (File No. 333-146641) and January 3, 2008 prospectus until further advised. This release corrects and should replace the release of January 4, 2008 in its entirety. Once conditions permit reliance on the prospectus included in the Registration Statement, the company will notify selling stockholders.
This notice is provided for informational purposes only, and does not represent a solicitation or offer to buy or sell any security. Any offer will be made my means of a current prospectus only. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About RxElite, Inc.
RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
investorrelations@rxelite.com
CONTACT: Corporate Information, +1-208-288-5550, or Toll Free
1-800-414-1901, fax, +1-208-288-1191; or Investor Relations, Charlie
Forshee of Segue Ventures LLC, +1-215-885-4981,
investorrelations@rxelite.com, for RxElite, Inc.
Web site: http://www.rxelite.com/
